Demethoxycurcumin inhibits energy metabolic and oncogenic signaling pathways through AMPK activation in triple-negative breast cancer cells

Journal of Agricultural and Food Chemistry

Volumn 61, Issue 26, 2013, Pages 6366-6375

  Shieh, Jiunn Min ^a,b   Chen, Yung Chan ^c   Lin, Ying Chao ^d,e,f   Lin, Jia Ni ^c   Chen, Wei Chih ^c   Chen, Yang Yuan ^g   Ho, Chi Tang ^h   Way, Tzong Der ^c,i  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^e TZU CHI UNIVERSITY   (Taiwan)

^f CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h RUTGERS UNIVERSITY   (United States)

ⁱ NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

AMPK; demethoxycurcumin; EGFR; triple negative breast cancer

Indexed keywords

ACETYL-COA CARBOXYLASE; AMPK; DEMETHOXYCURCUMIN; EGFR; EPIDERMAL GROWTH FACTOR RECEPTORS; EUKARYOTIC INITIATION FACTOR; MAMMALIAN TARGET OF RAPAMYCIN (MTOR); TRIPLE-NEGATIVE BREAST CANCERS;

ANTIBIOTICS; CHEMICAL ACTIVATION; CYTOLOGY; CYTOTOXICITY; DERIVATIVES; DISEASES; IMMUNOLOGY;

CELLS;

ANTINEOPLASTIC AGENT; CURCUMIN; DEMETHOXYCURCUMIN; DRUG DERIVATIVE; ENZYME ACTIVATOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ARTICLE; CARCINOGENESIS; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; ENERGY METABOLISM; FEMALE; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; ANTICARCINOGENIC AGENTS; CARCINOGENESIS; CELL LINE, TUMOR; CURCUMIN; ENERGY METABOLISM; ENZYME ACTIVATORS; FEMALE; HUMANS; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

CURCUMA LONGA; EUKARYOTA; MAMMALIA;

EID: 84879744896     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf4012455     Document Type: Article

References (40)

1. Arendos, M.; Bihan, C.; Delaloge, S.; Andre, F. Triple-negative breast cancer: are we making headway at least? Ther. Adv. Med. Oncol. 2012, 4, 195-210
2. Lehmann, B. D.; Bauer, J. A.; Chen, X.; Sanders, M. E.; Chakravarthy, A. B.; Shyr, Y.; Pietenpol, J. A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J. Clin. Invest. 2011, 121, 2750-2767
3. Brown, K. A.; Samarajeewa, N. U.; Simpson, E. R. Endocrine-related cancers and the role of AMPK Mol. Cell. Endocrinol. 2013, 366, 170-179
4. Hadad, S. M.; Baker, L.; Quinlan, P. R.; Robertson, K. E.; Bray, S. E.; Thomson, G.; Kellock, D.; Jordan, L. B.; Purdie, C. A.; Hardie, D. G.; Fleming, S.; Thompson, A. M. Histological evaluation of AMPK signalling in primary breast cancer BMC Cancer 2009, 9, 307
5. Inoki, K.; Zhu, T.; Guan, K. L. TSC2 mediates cellular energy response to control cell growth and survival Cell 2003, 115, 577-590
6. Faivre, S.; Kroemer, G.; Raymond, E. Current development of mTOR inhibitors as anticancer agents Nat. Rev. Drug Discov. 2006, 5, 671-688
7. Shackelford, D. B.; Shaw, R. J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression Nat. Rev. Cancer 2009, 9, 563-575
8. Migita, T.; Narita, T.; Nomura, K.; Miyagi, E.; Inazuka, F.; Matsuura, M.; Ushijima, M.; Mashima, T.; Seimiya, H.; Satoh, Y.; Okumura, S.; Nakagawa, K.; Ishikawa, Y. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer Cancer Res. 2008, 68, 8547-8554
9. Sivaprasad, U.; Abbas, T.; Dutta, A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells Mol. Cancer Ther. 2006, 5, 2310-2316
10. Nielsen, T. O.; Hsu, F. D.; Jensen, K.; Cheang, M.; Karaca, G.; Hu, Z.; Hernandez-Boussard, T.; Livasy, C.; Cowan, D.; Dressler, L.; Akslen, L. A.; Ragaz, J.; Gown, A. M.; Gilks, C. B.; van de Rijn, M.; Perou, C. M. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin. Cancer Res. 2004, 10, 5367-5374
11. Nogi, H.; Kobayashi, T.; Suzuki, M.; Tabei, I.; Kawase, K.; Toriumi, Y.; Fukushima, H.; Uchida, K. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer Oncol. Rep. 2009, 21, 413-417
12. Sutton, L. M.; Han, J. S.; Molberg, K. H.; Sarode, V. R.; Cao, D.; Rakheja, D.; Sailors, J.; Peng, Y. Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma Am. J. Clin. Pathol. 2010, 134, 782-787
13. Wright, L. E.; Frye, J. B.; Timmermann, B. N.; Funk, J. L. Protection of trabecular bone in ovariectomized rats by turmeric (Curcuma longa L.) is dependent on extract composition J. Agric. Food Chem. 2010, 58, 9498-9504
14. Suzuki, M.; Nakamura, T.; Iyoki, S.; Fujiwara, A.; Watanabe, Y.; Mohri, K.; Isobe, K.; Ono, K.; Yano, S. Elucidation of anti-allergic activities of curcumin-related compounds with a special reference to their anti-oxidative activities Biol. Pharm. Bull. 2005, 28, 1438-1443
15. Huang, M. T.; Ma, W.; Lu, Y. P.; Chang, R. L.; Fisher, C.; Manchand, P. S.; Newmark, H. L.; Conney, A. H. Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12- O -tetradecanoylphorbol-13- acetate-induced tumor promotion Carcinogenesis 1995, 16, 2493-2497
16. Hung, C. M.; Su, Y. H.; Lin, H. Y.; Lin, J. N.; Liu, L. C.; Ho, C. T.; Way, T. D. Demethoxycurcumin modulates prostate cancer cell proliferation via AMPK-induced down-regulation of HSP70 and EGFR J. Agric. Food Chem. 2012, 60, 8427-8434
17. Kim, J. H.; Shim, J. S.; Lee, S. K.; Kim, K. W.; Rha, S. Y.; Chung, H. C.; Kwon, H. J. Microarray-based analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: crucial involvement of the downregulation of matrix metalloproteinase Jpn. J. Cancer Res. 2002, 93, 1378-1385
18. Liu, L. C.; Tsao, T. C.; Hsu, S. R.; Wang, H. C.; Tsai, T. C.; Kao, J. Y.; Way, T. D. EGCG inhibits transforming growth factor-β-mediated epithelial-to-mesenchymal transition via the inhibition of Smad2 and Erk1/2 signaling pathways in nonsmall cell lung cancer cells J. Agric. Food Chem. 2012, 60, 9863-9873
19. Lin, V. C.; Tsai, Y. C.; Lin, J. N.; Fan, L. L.; Pan, M. H.; Ho, C. T.; Wu, J. Y.; Way, T. D. Activation of AMPK by pterostilbene suppresses lipogenesis and cell-cycle progression in p53 positive and negative human prostate cancer cells J. Agric. Food Chem. 2012, 60, 6399-6407
20. Huang, T. Y.; Tsai, T. H.; Hsu, C. W.; Hsu, Y. C. Curcuminoids suppress the growth and induce apoptosis through caspase-3-dependent pathways in glioblastoma multiforme (GBM) 8401 cells J. Agric. Food Chem. 2010, 58, 10639-10645
21. Lin, Y. T.; Wang, L. F.; Hsu, Y. C. Curcuminoids suppress the growth of pharynx and nasopharyngeal carcinoma cells through induced apoptosis J. Agric. Food Chem. 2009, 57, 3765-3770
22. Kim, K. Y.; Baek, A.; Hwang, J. E.; Choi, Y. A.; Jeong, J.; Lee, M. S.; Cho, D. H.; Lim, J. S.; Kim, K. I.; Yang, Y. Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation Cancer Res. 2009, 69, 4018-4026
23. Lihn, A. S.; Pedersen, S. B.; Lund, S.; Richelsen, B. The anti-diabetic AMPK activator AICAR reduces IL-6 and IL-8 in human adipose tissue and skeletal muscle cells Mol. Cell. Endocrinol. 2008, 292, 36-41
24. Sag, D.; Carling, D.; Stout, R. D.; Suttles, J. Adenosine 5′-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype J. Immunol. 2008, 181, 8633-8641
25. Nerstedt, A.; Johansson, A.; Andersson, C. X.; Cansby, E.; Smith, U.; Mahlapuu, M. AMP-activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by suppressing phosphorylation of signal transducer and activator of transcription 3 (STAT3) Diabetologia 2010, 53, 2406-2416
26. Bromberg, J.; Wang, T. C. Inflammation and cancer: IL-6 and STAT3 complete the link Cancer Cell 2009, 15, 79-80
27. Simon, A.; Allais, D. P.; Duroux, J. L.; Basly, J. P.; Durand-Fontanier, S.; Delage, C. Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure-activity relationships Cancer Lett. 1998, 129, 111-116
28. Korsse, S. E.; Peppelenbosch, M. P.; van Veelen, W. Targeting LKB1 signaling in cancer Biochim. Biophys. Acta 2012, 1835, 194-210
29. Montero, J. C.; Esparís-Ogando, A.; Re-Louhau, M. F.; Seoane, S.; Abad, M.; Calero, R.; Ocaña, A.; Pandiella, A. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene 2012, DOI: 10.1038/onc.2012.572.
30. Fedele, P.; Calvani, N.; Marino, A.; Orlando, L.; Schiavone, P.; Quaranta, A.; Cinieri, S. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going? Crit. Rev. Oncol. Hematol. 2012, 84, 243-251
31. Zhang, B. B.; Zhou, G.; Li, C. AMPK: an emerging drug target for diabetes and the metabolic syndrome Cell Metab. 2009, 9, 407-416
32. Lupu, R.; Menendez, J. A. Targeting fatty acid synthase in breast and endometrial cancer: an alternative to selective estrogen receptor modulators? Endocrinology 2006, 147, 4056-4066
33. Zhou, W.; Simpson, P. J.; McFadden, J. M.; Townsend, C. A.; Medghalchi, S. M.; Vadlamudi, A.; Pinn, M. L.; Ronnett, G. V.; Kuhajda, F. P. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells Cancer Res. 2003, 63, 7330-7337
34. Vilar, E.; Perez-Garcia, J.; Tabernero, J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors Mol. Cancer Ther. 2011, 10, 395-403
35. Berishaj, M.; Gao, S. P.; Ahmed, S.; Leslie, K.; Al-Ahmadie, H.; Gerald, W. L.; Bornmann, W.; Bromberg, J. F. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer Breast Cancer Res. 2007, 9, R32
36. Diaz, N.; Minton, S.; Cox, C.; Bowman, T.; Gritsko, T.; Garcia, R.; Eweis, I.; Wloch, M.; Livingston, S.; Seijo, E.; Cantor, A.; Lee, J. H.; Beam, C. A.; Sullivan, D.; Jove, R.; Muro-Cacho, C. A. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression Clin. Cancer Res. 2006, 12, 20-28
37. Hoadley, K. A.; Weigman, V. J.; Fan, C.; Sawyer, L. R.; He, X.; Troester, M. A.; Sartor, C. I.; Rieger-House, T.; Bernard, P. S.; Carey, L. A.; Perou, C. M. EGFR associated expression profiles vary with breast tumor subtype BMC Genomics 2007, 8, 258
38. Ferraro, D. A.; Gaborit, N.; Maron, R.; Cohen-Dvashi, H.; Porat, Z.; Pareja, F.; Lavi, S.; Lindzen, M.; Ben-Chetrit, N.; Sela, M.; Yarden, Y. Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 1815-1820
39. Sinha, D.; Biswas, J.; Sung, B.; Aggarwal, B. B.; Bishayee, A. Chemopreventive and chemotherapeutic potential of curcumin in breast cancer Curr. Drug Targets 2012, 13, 1799-1819
40. Ireson, C.; Orr, S.; Jones, D. J.; Verschoyle, R.; Lim, C. K.; Luo, J. L.; Howells, L.; Plummer, S.; Jukes, R.; Williams, M.; Steward, W. P.; Gescher, A. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production Cancer Res. 2001, 61, 1058-1064